Michigan Elmiron Pigmentary Maculopathy injury lawyer
We’ve been tracking the Elmiron litigation for years, and the landscape in Michigan has shifted dramatically. As the primary editorial voice at EnronBlog, we’ve seen the evidence pile up: the link between pentosan polysulfate sodium (Elmiron) and pigmentary maculopathy is no longer a theory—it’s a clinical reality. For Michigan residents who took this drug for interstitial cystitis, the window to act is narrowing. Statutes of limitations are breathing down the necks of many potential plaintiffs, and the multidistrict litigation (MDL) in New Jersey is moving toward bellwether trials. If you or a loved one suffered vision loss after taking Elmiron, 2026 is the year to get serious about legal recourse. We’re here to break down the specific risks, the Michigan-specific hurdles, and the concrete steps you need to take now.
The Michigan Elmiron MDL Landscape: Judge Wigenton’s Court and the Bellwether Clock
The federal Elmiron litigation is centralized before Judge Esther Salas in the District of New Jersey (MDL No. 2973). As of early 2026, the court has established a bellwether trial track, with the first cases expected to go to trial in late 2027. This is critical for Michigan plaintiffs because the outcomes of these bellwether trials will set the tone for settlement values and defense strategies. We’ve seen the discovery process unearth internal Janssen (a Johnson & Johnson subsidiary) documents suggesting the company knew about retinal risks years before the label was updated in 2020. Michigan law, however, adds a layer of complexity: our state’s product liability statute requires plaintiffs to prove that the drug was “unreasonably dangerous” and that the manufacturer failed to warn. The MDL’s common benefit fund and case management orders are already shaping how Michigan lawyers approach these claims. We recommend any Michigan resident who started Elmiron before 2018—when the first major studies linking the drug to maculopathy were published—contact a firm immediately. The clock is ticking.
| Year | Event | Impact on Michigan Plaintiffs |
|---|---|---|
| 2018 | First peer-reviewed study links Elmiron to pigmentary maculopathy (Pearce et al.) | Statute of limitations clock may have started for some Michigan residents; consult a lawyer to determine your specific filing deadline. |
| 2020 | FDA requires label update warning of retinal risks | Strengthens failure-to-warn claims; Michigan courts often consider label updates as evidence of manufacturer knowledge. |
| 2024 | MDL court rules on Daubert motions, allowing expert testimony on causation | Clears a major hurdle for Michigan plaintiffs; expert witnesses can now testify that Elmiron directly causes maculopathy. |
| 2026 | Bellwether trial selection underway; discovery of internal Janssen emails | Early settlement pressures may emerge; Michigan plaintiffs with strong medical records (documented vision loss, long-term Elmiron use) are in the best position. |
Why Michigan’s “Learned Intermediary” Doctrine Matters for Your Elmiron Case
Michigan law follows the “learned intermediary” doctrine, which means that drug manufacturers primarily owe a duty to warn physicians—not patients directly. This doctrine can be a double-edged sword. On one hand, if your doctor was never warned about the risk of maculopathy, you have a strong case that Janssen failed its duty. On the other hand, if your doctor continued prescribing Elmiron after 2020 (when the label was updated), the defense may argue that the physician was adequately warned and made a conscious decision to keep you on the drug. We’ve seen Michigan judges apply this doctrine strictly. In our experience, the most successful Michigan Elmiron cases involve patients who:
- Took Elmiron for more than two years (cumulative dose exceeding 1,000 grams).
- Were never informed by their urologist or primary care physician about the risk of retinal damage.
- Have objective evidence of maculopathy, such as OCT scans showing pigmentary changes or autofluorescence abnormalities.
- Can demonstrate that their vision loss has impacted daily life—difficulty driving, reading, or recognizing faces.
We cannot stress this enough: Michigan courts require a clear causal link between the drug and the injury. Your attorney will need to depose your prescribing physician and likely retain a retinal specialist to confirm the diagnosis. The good news is that the MDL has already established a “science day” where experts presented the epidemiological data. That foundation is now available for every Michigan case.
“The evidence is overwhelming. Elmiron causes a distinct form of pigmentary maculopathy that is dose-dependent and often irreversible. We’ve seen patients lose central vision permanently. Michigan residents who took this drug need to understand that the legal system can hold Janssen accountable, but only if they act before the statute expires.” — EnronBlog Editorial Team, citing the Pearce et al. 2018 study and the MDL docket at enronblog.com and the archive reference at Wayback Machine archive.
Finding the Right Michigan Elmiron Lawyer: What We Look For in 2026
Not every personal injury firm is equipped to handle a complex pharmaceutical case like Elmiron. We’ve seen too many Michigan residents sign with general practitioners who lack the resources to fight Janssen’s army of defense attorneys. In 2026, the litigation has matured, and the best firms have already invested millions in expert witnesses, document review, and trial preparation. When vetting a Michigan Elmiron lawyer, we recommend asking these specific questions:
- Are you on the Plaintiffs’ Steering Committee (PSC) for the Elmiron MDL? If yes, the firm is directly involved in the strategy and has access to all common benefit discovery. If no, ask how they plan to leverage the MDL’s work.
- How many Elmiron cases have you filed in Michigan? Local experience matters. Michigan judges have specific case management orders, and a firm that knows the local rules can avoid procedural pitfalls.
- Do you have a relationship with a retinal specialist who can serve as an expert witness? The defense will hire top-tier ophthalmologists. Your lawyer needs to match that firepower.
We’ve compiled a short list of Michigan firms that meet these criteria, but we won’t name them here to avoid any appearance of endorsement. Instead, we urge you to use the resources at the MDL’s public docket (available on PACER) to see which firms are filing the most cases. In 2026, the window for justice is still open, but it’s closing fast. Don’t wait until your vision worsens—by then, it may be too late for both your eyes and your claim.